한글목차

개요

치은염은 잇몸 조직의 염증성 질환으로 가장 흔한 원인은 세균 감염입니다. 치주염과 달리 부착 부위의 손실이 없으므로 접합 상피의 이동이 없습니다. 증상은 잇몸 상피와 결합조직의 연조직 부위에만 국한됩니다. 치주질환 중 치은염은 가장 흔한 질환입니다.

치은염은 치은열구 내 또는 치은열구 부근에 존재하는 미생물의 플라크 침착에 의해 발생합니다. 치은염의 병인과 밀접한 관련이 있는 미생물에는 Streptococcus, Fusobacterium, Actinomyces, Veillonella, Treponema 등이 있습니다. 박테로이데스, 카프노사이토파가, 에이케넬라 역시 이 질환의 병인과 관련이 있을 수 있습니다.

시장 역학: 시장 성장 촉진요인과 시장 성장 억제요인

인지도 향상 및 관리 개선

또한, 가처분 소득 증가와 구강 건강의 중요성에 대한 인식이 높아짐에 따라 치은염 치료에 사용되는 제품을 포함한 고품질 구강 관리 제품에 대한 수요가 증가하고 있습니다. 이에 따라 혁신적인 성분의 치약, 구강 세정제, 첨단 치과용 기기 등 다양한 신제품과 신기술이 시장에 출시되고 있습니다.

예를 들어, 2022년 5월 유럽치주과학회(EFP)가 주최하는 세계 인식 개선 캠페인 '잇몸 건강의 날 2022'는 'Treat your Gums'를 슬로건으로 내걸었습니다. 이 행사는 치은염, 치주염, 임플란트 주위 점막염, 임플란트 주위염과 같은 치주질환이 구강 및 전신 건강에 미치는 악영향을 대중에게 알리는 것을 목적으로 합니다. 이 캠페인은 치주질환의 예방과 조기 발견, 그리고 필요한 경우 효과적인 치료를 촉구하고 있습니다.

또한 치은염의 유병률 증가, 치료 옵션의 발전, 주요 기업 등의 제휴 및 투자가 예측 기간 동안 시장 성장을 더욱 촉진할 것입니다.

시장 역학: 억제요인

만성 치은염은 당뇨병, 뇌졸중, 류마티스 관절염, 관상동맥질환 등 전신질환과 관련이 있습니다. 가장 흔한 합병증은 치은염으로 치아 손실로 이어지는 치은염입니다. 항치은염제는 구강 내 자극, 염증, 구강 건조증, 이물감을 유발할 수 있으며, 과다 사용은 화학적 화상을 유발할 수 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 인지도 향상과 관리 개선
    • 치료 옵션의 진보
  • 성장 억제요인
    • 질환에 수반하는 합병증
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 러시아·우크라이나 전쟁의 영향 분석
• DMI의 의견

제6장 COVID-19 분석

제7장 유형별

• 플라크 유발성 치은염
• 영양성 치은염
• 호르몬성 치은염
• 약제성 치은염

제8장 치료 유형별

• 비외과적 치료
• 외과적 치료

제9장 판매채널별

• 최종사용자
• 유통 채널

제10장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카

제11장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• 인수합병(M&A)분석

제12장 기업 개요

• Citron Pharma
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 동향
• Pfizer plc
• Novartis AG
• Wellona Pharma
• Medtronic
• Aspen Pharma
• Harfins Instruments
• AsaDental
• Advil
• Ora Pharma

제13장 부록

영문목차

Overview

Gingivitis is an inflammatory condition of the gingival tissue, most commonly caused by bacterial infection. Unlike periodontitis, there is no attachment loss and therefore no migration of the junctional epithelium. The condition is restricted to the soft-tissue area of the gingival epithelium and connective tissue. Among all the periodontal diseases, gingivitis is considered to be the commonest.

Gingivitis is caused by microbial plaque deposits located in or close to the gingival sulcus. The microorganisms more strongly associated with the etiology of gingivitis include species of Streptococcus, Fusobacterium, Actinomyces, Veillonella, and Treponema. Bacteroides, Capnocytophaga, and Eikenella are also potentially linked to the etiology of the disease.

Market Dynamics: Drivers and Restraints

Rise in awareness and improved management

In addition, increasing disposable incomes and growing awareness of the importance of oral health are driving demand for high-quality oral care products, including those used for gingivitis treatment. This has led to the introduction of new products and technologies in the market, including innovative toothpaste formulations, mouthwashes, and advanced dental instruments.

For instance, in May 2022, Treat your Gums was the slogan for Gum Health Day 2022, a worldwide awareness campaign organised by the European Federation of Periodontology (EFP). The event aims to inform the public of the detrimental effects of gum diseases - gingivitis, periodontitis, peri-implant mucositis, and peri-implantitis on both oral and overall health. The campaign calls for the prevention, early detection, and where necessary effective treatment of gum diseases.

Furthermore, a rise in the prevalence of gingivitis, a rise in advancements in treatment options, collaborations and investments by key players and others will further drive the market to grow during the forecast period.

Market Dynamics: Restraint

Chronic gingiva inflammation is linked to systemic conditions like diabetes, stroke, rheumatoid arthritis, and coronary artery disease. The most common complication is gingivitis, which leads to tooth loss. Anti-gingivitis agents can cause mouth irritation, inflammation, dry mouth, and unusual tastes, with overuse potentially causing chemical burns.

Segment Analysis

The global gingivitis treatment is segmented based on treatment type, sales channel and region.

The non-surgical treatment from the treatment type segment accounted for approximately 41.2% of the market share

The non-surgical segment from the treatment type segment accounted for 41.2% and it is expected to dominate during the forecast period. Non-surgical medical procedures are used to diagnose, measure, monitor or treat problems such as diseases or injuries that don't require surgery. Owing to the non-surgical treatment are minimally invasive, cost-effective, patient-centric approach will drive this segment during the forecast period.

For instance, in April 2022, The University of Texas Health Science Center at San Antonio (UT Health San Antonio) received a four-year award of $2.4m from the US National Institutes of Health (NIH) to study the usage of antibiotics for periodontal disease, commonly called gum disease.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to a growing awareness of the importance of oral health in North America, significant technological advances in gingivitis treatment products, including new toothpaste formulations, advanced dental instruments, and innovative oral care products. Dental insurance is widely available in North America, which makes it easier for people to access gingivitis treatment products and services, novel formulation launches and others.

In July 2022, Pendopharm, a division of Pharmascience Inc., is pleased to introduce PrPERICHLOR WITHOUT ALCOHOL, a new alcohol-free formulation of its gingivitis mouthwash.PrPERICHLOR WITHOUT ALCOHOL is indicated for use as part of a professional program for the treatment of moderate to severe gingivitis, and for management of associated gingival bleeding and inflammation between dental visits.

COVID-19 Impact Analysis

The COVID-19 pandemic led to reduced opening hours and the closure of dental practices, except in the case of emergency procedures. This has limited people's ability to access routine care. Also, COVID-19 causes organ failure, systemic diseases, and poor oral health, including periodontal disease. The cytokine storm, induced by excessive proinflammatory cytokines, leads to tissue damage.

Common risk factors include obesity, diabetes, cardiovascular disease, age, and smoking. Symptoms of COVID-19 infection include ulcers, erosions, white-red plaques, post-inflammatory pigmentation, petechia, erythema multiforme-like lesions, and necrotizing periodontal disease, with gingiva being a common site of involvement.

Competitive Landscape

The major global players in the gingivitis treatment market include: Citron Pharma, Pfizer plc, Novartis AG, Wellona Pharma, Medtronic, Aspen Pharma, Harfins Instruments, AsaDental, Advil, Ora Pharma and among others.

Key Developments

• In May 2023, Bausch Health Companies Inc. and its oral health care business, OraPharma, stated its collaboration with World Series Champion, Alex Rodriguez, to launch a national awareness campaign about the prevalence and impact of gum disease. The campaign launch is timed to Oral Health Month recognized throughout June and features Alex as a patient ambassador.
• In January 2023, Ashland launched saffragyl, a biofunctional that transforms oral health into a daily beauty regimen by proposing a natural, safe, and effective bioactive to take care of the biology of the gingiva. It offers a preventive answer to gums prone to gingivitis and is microbiome-friendly, gum-friendly and can be used daily.
• In October 2022, it was stated that a rapid test for gum disease was being developed by researchers at the University of Birmingham. The probe, designed for use in point-of-care settings such as dental surgeries or pharmacies, is expected to aid in the early detection of heart or lung disease, type 2 diabetes, and rheumatoid arthritis.

Why Purchase the Report?

• To visualize the global gingivitis treatment market segmentation-based type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of gingivitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global gingivitis treatment market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Sales Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Driver
    • 4.1.1.1. Rise in the awareness and improved management
    • 4.1.1.2. Advancements in treatment options
  • 4.1.2. Restraints
    • 4.1.2.1. Complications associated with the disease
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Plaque Induced Gingivitis*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Nutritional Gingivitis
• 7.4. Hormonal Gingivitis
• 7.5. Drug-Induced Gingivitis

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Non-Surgical *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Surgical

9. By Sales Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 9.1.2. Market Attractiveness Index, By Sales Channel
• 9.2. End User *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Distribution Channel

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Citron Pharma
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Pfizer plc
• 12.3. Novartis AG
• 12.4. Wellona Pharma
• 12.5. Medtronic
• 12.6. Aspen Pharma
• 12.7. Harfins Instruments
• 12.8. AsaDental
• 12.9. Advil
• 12.10. Ora Pharma

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us